TD Cowen analyst Ritu Baral downgraded Spero Therapeutics (SPRO) to Hold from Buy without a price target The firm cites a lack of clarity on catalyst timing following discontinuation of the SPR720 Phase 2 program for the downgrade. TD now sees a lack of clarity on meaningful catalyst flow for the shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRO: